Sarcoma
Conditions
Keywords
Soft Tissue Sarcoma, Adoptive Cell Therapy
Brief summary
This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment
Interventions
DRUGTIL
Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
DRUGInterleukin-2
Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
DRUGFludarabine
Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
DRUGCyclophosphamide
Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
Iovance Biotherapeutics, Inc.
The V Foundation for Cancer Research
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
No
Inclusion criteria
* Participants must fulfill all of the following criteria to be eligible for the study at the time of tumor resection and initiation of TIL expansion. * Stated willingness to comply with all study procedures and availability for the duration of the study * Participants must have metastatic, high-grade soft tissue sarcoma, all subtypes will be eligible * Residual measurable disease after resection of target lesion(s) for TIL growth * Eastern Cooperative Oncology Group (ECOG) 0 to 1. ECOG performance status of 0 to 1 will be inferred if the patient's level of energy is ≥ 50% of baseline. * Participants must have progressed on at least one prior standard of care treatment regimen for metastatic disease. * A negative pregnancy test (urine or serum) must be documented at screening for women of childbearing potential. * A MUGA scan (ejection fraction \> 50% is required) ≤ 6 months prior to lymphodepletion. * Pulmonary function tests should be completed ≤ 6 months prior to lymphodepletion and forced expiratory volume (FEV1) \> 65% or FVC \> 65% of predicted are required * Adequate renal, hepatic, and hematologic function, including creatinine of ≤ 1.7 gm/dL, total bilirubin ≤ 2.0 mg/dL, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL, AST and ALT of less than 3 X institutional upper limit of normal, hemoglobin of 8 gm/dL or more, white blood cells of 3000 per mm\^3 and total granulocytes of 1000 per mm\^3 or more, and platelets of 100 000 per mm\^3 or more. * Participants must have a positive screening EBV antibody titre on screening test. * Participants that have had previously grown sterile, validated TILs under good manufacturing practice conditions meeting the above criteria are eligible using the previously established TIL product stored in the Cell Therapies Core facility for up to 2 years after harvesting. * Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the participant agrees to continue to use a method of contraception throughout the study such as: barrier (i.e. condom, diaphragm), hormonal, IUD, or sponge plus spermicide. * Prothrombin time (PT) and partial thromboplastin time (PTT) within 1.5 times the institutional upper limit of normal * Participants with echocardiogram (EKG) within 14 days of initiation of chemotherapy demonstrating no new rhythm, axis, or ST segment If new ST changes are present, patients may be included if cardiac stress test indicates no evidence of inducible cardiac ischemia. * Urinalysis within 14 days demonstrating no evidence of a urinary tract infection. * Participants with evidence of ongoing disease regression that is attributed to a therapy that is not part of the trial and that was administered after TIL harvest and expansion but prior to adoptive transfer of TILs should continue on prior therapy and may be treated with TIL only if their disease is stable or there is evidence of progressive disease. In this event as described above, the TIL will be frozen and stored for future use, in the event of progression, prior to the rapid expansion step.
Exclusion criteria
* Participants with active systemic infections requiring intravenous antibiotics, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system are excluded. * Participants that have completed a chemotherapy regimen given with the intent of lymphodepletion or cellular immunotherapy which included non-myeloablative lymphodepletion strategy. * Participants testing positive for HIV titer, hepatitis B surface antigen, human T-cell leukemia-lymphoma virus (HTLV) I or II antibody, or both rapid plasma regain (RPR) and fluorescent treponemal antibody (FTA) are excluded. Participants with hepatitis C antibody must have a negative (undetectable) viral load by polymerase chain reaction (PCR). * Participants who are pregnant or nursing are excluded. * Participants needing chronic immunosuppressive systemic steroids are excluded * Participants with autoimmune diseases that require immunosuppressive medications are excluded * Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated * Participants with central nervous system metastases will be excluded. * Inability to comprehend and give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experienced Serious Adverse Events and Adverse Events | Baseline to 12 months | Participants able to safely tolerate preparatory lymphodepletion, infusion of tumor-infiltrating lymphocytes (TIL) and subsequent IL-2, as measured by adverse events and serious adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Objective Antitumor Response | At 12 weeks | Number of participants with objective response (Complete Response (CR) + Progressive Response (PR)) rate at 12 weeks following TIL infusion, as measured by RECIST v1.1 |
| Number of Participants With Circulating Tumor-infiltrating Lymphocytes (TIL) Product at 6 Weeks | At 6 weeks | Number of participants with persistence of TIL infusion product at 6 weeks following treatment, as measured by T-cell receptor repertoire comparison between the infusion product and circulating Peripheral blood mononuclear cell (PBMC). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJohn Mullinax, MD
Moffitt Cancer Center
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Infusion of Tumor-infiltrating Lymphocyte Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB). All participants will receive not less than 10\^9, and up to 1x10\^12 T cells in ≥250 mL NS as an inpatient by IV.
Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an IV bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated.
TIL: Participants will receive an infusion of TIL after tumor resection and TIL product is generated.
Interleukin-2 (IL-2): Participants will receive IL-2 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
Fludarabine: Participants will receive an IV infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
Cyclophosphamide: Participants will receive Cyclophosphamide 60 mg/kg/day IV in 250 mL NS over approximately 2 hours, 7 days prior to T-Cell infusion | 9 |
| Total | 9 |
Baseline characteristics
| Characteristic | Infusion of Tumor-infiltrating Lymphocyte |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Region of Enrollment United States | 9 participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 9 |
| other Total, other adverse events | 9 / 9 |
| serious Total, serious adverse events | 3 / 9 |
Outcome results
Primary
Number of Participants Who Experienced Serious Adverse Events and Adverse Events
Participants able to safely tolerate preparatory lymphodepletion, infusion of tumor-infiltrating lymphocytes (TIL) and subsequent IL-2, as measured by adverse events and serious adverse events.
Time frame: Baseline to 12 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Infusion of Tumor-infiltrating Lymphocyte | Number of Participants Who Experienced Serious Adverse Events and Adverse Events | Adverse event | 4 Participants |
| Infusion of Tumor-infiltrating Lymphocyte | Number of Participants Who Experienced Serious Adverse Events and Adverse Events | No adverse events noted | 5 Participants |
Secondary
Number of Participants With Circulating Tumor-infiltrating Lymphocytes (TIL) Product at 6 Weeks
Number of participants with persistence of TIL infusion product at 6 weeks following treatment, as measured by T-cell receptor repertoire comparison between the infusion product and circulating Peripheral blood mononuclear cell (PBMC).
Time frame: At 6 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Infusion of Tumor-infiltrating Lymphocyte | Number of Participants With Circulating Tumor-infiltrating Lymphocytes (TIL) Product at 6 Weeks | 5 Participants |
Secondary
Number of Participants With Objective Antitumor Response
Number of participants with objective response (Complete Response (CR) + Progressive Response (PR)) rate at 12 weeks following TIL infusion, as measured by RECIST v1.1
Time frame: At 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Infusion of Tumor-infiltrating Lymphocyte | Number of Participants With Objective Antitumor Response | 0 Participants |